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Chromatin regulation is essential for
maintaining cellular-fate decisions during
immune cell development; however, its
activity in mature regulatory T cells is less
clear. Bluestone and colleagues show
that the chromatin modifier Ezh2 bridges
cellular activation and the maintenance of
Treg identity by responding to CD28
signals and supporting the Foxp3-driven
gene-expression program.
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Regulatory T cells (Treg cells) are required for im-
mune homeostasis. Chromatin remodeling is essen-
tial for establishing diverse cellular identities, but
how the epigenetic program in Treg cells is main-
tained throughout the dynamic activation process
remains unclear. Here we have shown that CD28
co-stimulation, an extracellular cue intrinsically re-
quired for Treg cell maintenance, induced the chro-
matin-modifying enzyme, Ezh2. Treg-specific abla-
tion of Ezh2 resulted in spontaneous autoimmunity
with reduced Foxp3+ cells in non-lymphoid tissues
and impaired resolution of experimental autoimmune
encephalomyelitis. Utilizing a model designed to
selectively deplete wild-type Treg cells in adult
mice co-populated with Ezh2-deficient Treg cells,
Ezh2-deficient cells were destabilized and failed to
prevent autoimmunity. After activation, the transcrip-
tome of Ezh2-deficient Treg cells was disrupted, with
altered expression of Treg cell lineage genes in a
pattern similar to Foxp3-deficient Treg cells. These
studies reveal a critical role for Ezh2 in the mainte-
nance of Treg cell identity during cellular activation.
INTRODUCTION
Regulatory T cells (Treg cells) are a subset of T lymphocytes that
suppress auto-reactive effector T cells and are essential for im-
mune homeostasis. Treg cell maintenance is critical because
their loss leads to the rapid onset of fatal autoimmunity (Kim
et al., 2007). CD28 signaling is essential for the generation and
maintenance of Treg cells (Tai et al., 2005; Tang et al., 2003),
which, in the case of CD28-deficient NODmice, leads to exacer-
bated autoimmunity due to disrupted Treg cell homeostasis
(Lenschow et al., 1996; Salomon et al., 2000). While CD28
signaling contributes to Treg cell identity via multiple mecha-
nisms, including induction of Foxp3 itself, our previous studies
indicated that CD28 signals also regulate enzymes that controlchromatin structure (Martı´nez-Llordella et al., 2013). Chro-
matin-mediated support of Treg cell identity might be especially
important in the context of inflamed tissues where activated Treg
cells must preserve their core gene-expression program in the
face of a complex milieu of extracellular cues.
The epigenetic regulator Enhancer of Zeste Homolog 2 (Ezh2)
functions primarily within the multi-subunit polycomb repressive
complex 2 (PRC2) and catalyzes the tri-methylation of lysine 27
on the exposed N-terminal tail of histone H3 (H3K27me3) (Mar-
gueron and Reinberg, 2011). H3K27me3 recruits protein com-
plexes involved in chromatin compaction and is associated
with inactive genes (Spivakov and Fisher, 2007). Ezh2 and
H3K27me3-marked histones have been shown to be critical for
proper B and T cell lineage development (Mandal et al., 2011;
Raaphorst et al., 2001; Su et al., 2003; Su et al., 2005), cytokine
gene regulation in distinct T helper cell subsets (Chang and
Aune, 2007; Jacob et al., 2008; Koyanagi et al., 2005), and T
helper-1 (Th1) versus Th2 cell polarization in vitro (Tumes et al.,
2013). By comparison, Treg cells have a distinct H3K27me3
landscape compared to naive or polarized CD4+ T helper cells
(Wei et al., 2009). Furthermore, Ezh2 can directly control Foxp3
expression (Xiong et al., 2012) and, during inflammatory re-
sponses, Ezh2 is recruited by Foxp3 to repress key genes in
Treg cells (Arvey et al., 2014). However, genetic ablation of
Ezh2 does not disrupt induced Treg cell generation in vitro
(Tumes et al., 2013; Zhang et al., 2014). Therefore, the impor-
tance of Ezh2 to Treg cell stability and function, especially in
naturally arising Treg cells in vivo, is unresolved.
Here we have shown that Ezh2 is induced after CD28-
mediated activation and stabilizes the Treg cell transcriptional
program. Mice with Ezh2 deficiency targeted specifically to
Foxp3-expressing cells succumbed to autoimmunity and were
incapable of resolving an induced, acute form of autoimmune
disease. Activated Ezh2-deficient Treg cells showed selective
destabilization of Treg cell signature genes and a pronounced in-
duction of genes normally repressed in Treg cells after activa-
tion. The effect of Ezh2 deletion in activated Treg cells was
most prominent in non-lymphoid tissue sites where the fre-
quency of Foxp3+ cells and the stability of Foxp3 expression
were reduced. Thus, Ezh2 is critical for proper Treg cell function
by supporting Foxp3-driven gene expression patterns following
cellular activation.Immunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc. 227
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C Figure 1. CD28-Dependent Induction of
Ezh2 in T Regulatory Cells
(A) Microarray analysis to reveal CD28-dependent
genes by comparison of human naive CD4+ T cells
thatwere unstimulated, stimulatedwith anti-CD3, or
stimulated with anti-CD3 and anti-CD28 antibodies
for 24 hr. Heat map of known histone lysine deme-
thylases, methyltransfereses, acetyltransferases,
and deacetylases that were significantly differen-
tially expressed by comparing anti-CD3+CD28-
stimulated versus unstimulated and anti-CD3+
CD28-stimulated versus anti-CD3 stimulated (36
out of all 9,824 DEGs, FDR < 0.05) are plotted.
(B) Ezh2 expression in sorted mouse Treg cells
24 hr after stimulation with anti-CD3 or anti-CD3
and anti-CD28 antibody-coated beads relative to
unstimulated Treg cells (n = 2 per condition).
(C) Ezh2 Western blot analysis of CD28-deficient
(D/D) or WT (+/+) mouse Treg cells (from Foxp3-
cre;CD28fl/fl mice) 36 hr after stimulation with anti-
CD3 and anti-CD28 antibody-coated beads.
(D) H3K27me3 staining in naive versus activated
Treg cells in vivo by gating populations based on
CD44 and CD62L expression.
Data are mean ± SEM and representative of at
least three experiments unless noted otherwise.
See also Figure S1.RESULTS
CD28-Dependent Induction of Ezh2 in
T Regulatory Cells
A survey of all differentially expressed histone acetyltransferase,
methyltransferase, and demethylase genes upon activation of
human naive CD4+ T cells (Martı´nez-Llordella et al., 2013) re-
vealed that Ezh2, which encodes an H3K27 methyltransferase,
was the most highly induced CD28-dependent chromatin mod-
ifier (Figure 1A). Blockade of CD28 co-stimulation, either using
CD28- or B7-deficient mice, confirmed the CD28 co-stimula-
tion-dependent induction of Ezh2 protein in mouse T cells (Fig-
ures S1A and S1B). CD28 co-stimulation also induced Ezh2
mRNA and protein in murine Treg cells (Figures 1B and 1C).
Furthermore, there was concordance between reduced Ezh2
expression and reduced enzymatic activity in activated CD28-
deficient Treg cells, based on deposition of tri-methylated
Lys27 histone H3 (H3K27me3) marks by quantitative flow
cytometric analysis (Figure S1C). The specificity of the anti-
H3K27me3 antibody, and lack of redundancy with Ezh1 in acti-
vated Treg cells, was confirmed by H3K27me3 staining of
Ezh2-deficient Treg cells (Figures S1D–S1G). Finally, activated
CD44hiCD62Llo Treg cells had more H3K27me3 marks than
resting CD44loCD62Lhi cells in vivo (Figure 1D). Thus, CD28-
mediated co-stimulation in Treg cells was required to induce
Ezh2 expression and activity.
Phenotypic Analysis Does Not Reveal Defects in
Ezh2-Deficient Treg Cells
To directly investigate the role of Ezh2 in Treg cells in vivo, we
generated mice with partial, Foxp3-GFP-hcre;Ezh2fl/+ (termed
Treg.Ezh2D/+ mice), or complete deletion of Ezh2 in Treg cells,
Foxp3-GFP-hcre;Ezh2fl/fl (termed Treg.Ezh2D/D mice) (Su et al.,
2003; Zhou et al., 2008). The frequency of Foxp3+ Treg cells228 Immunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc.(as a percent of total CD4+ T cells) was increased in lymph nodes
and thymi of Treg.Ezh2D/D mice but unchanged in the blood and
spleen (Figures 2A and 2B). Phenotypic analysis by flow cytom-
etry showed no differences in the expression of many important
Treg-associated proteins (Figure 2C), although markers of Treg
cell activation (e.g., CTLA-4, PD-1, CD103, GITR) were increased
in Treg cells of older Treg.Ezh2D/Dmice. In addition, Ezh2D/D Treg
cells from Treg.Ezh2D/D mice had higher frequencies of CD69+
cells and greater proportions of CD44hiCD62Llo cells at all time
points examined as compared to Treg cells from Treg.Ezh2D/+ lit-
termates (Figures 2D and 2E). Finally, CD62Lhi Ezh2D/D Treg cells
maintained normal suppressive capacity in vitro (Figure 2F).
Thus, Treg cells from Treg.Ezh2D/D mice are not reduced in fre-
quency, are phenotypically normal and are capable of being acti-
vated and functioning properly. The increased frequency and
activation of Treg cells in Treg.Ezh2D/D mice might result from
increased demand for Treg cell mediated tolerance, a phenom-
enon commonly described in mice with dysfunctional or
depleted Treg cells (Pierson et al., 2013; Zhou et al., 2008).
Uncontrolled T Cell Activation and Tissue Infiltration in
Treg.Ezh2D/D Mice
To investigate whether Ezh2 deletion in Treg cells disrupts Treg
function in vivo, we followed Treg.Ezh2D/+ and Treg.Ezh2D/D
mice over time. Young Treg.Ezh2D/D mice (6 to 8 weeks old)
had increased lymph node cellularity compared to Treg.Ezh2D/+
littermates (Figures S2A and S2B). However, the proportions of
activated CD44hiCD62Llo CD4+ and CD8+ T cells, as well as
CD44hiCD62Lhi CD8+ T cells (TCM), were increased most notice-
ably in older Treg.Ezh2D/D mice (Figures 3A and 3B). In addition,
unlike Treg.Ezh2D/+ mice, Treg.Ezh2D/D mice displayed various
symptoms of autoimmunity, such as reduced weight, hair loss,
scaly tails, and swelling around their eyes and ears (Figures
S2C and S2D). Examination of non-lymphoid tissues, including
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B Figure 2. Ezh2-Deficient Treg Cells Are Un-
altered in Lymphoid Tissues
(A) Representative flow cytometric analysis of the
frequencies of Treg cells (as percentage of gated
CD4+ cells) in peripheral lymph nodes and spleen.
(B) Quantification of data obtained as in (A) for all
lymphoid tissues (perLN, inguinal and axillary;
mesLN, mesenteric; Spln, spleen; Bld, blood; Thy,
thymus).
(C) Phenotypic analysis of Treg cells (solid lines)
from perLNs of indicated mice or CD4+Foxp3
cells from Treg.Ezh2D/D mice (shaded, CD4T.
Ezh2fl/fl) by staining for indicated proteins at 8 or
24 weeks of age.
(D and E) Flow cytometric analysis of Treg cells for
CD69 (D) or CD44 versus CD62L expression (E)
and quantification of results from mice analyzed
between 8 and 17 weeks of age.
(F) In vitro Treg cell suppression assay monitoring
the percentage of undivided CD4+ T cells (Teff) by
dilution of CTV three days after co-culture with
indicated ratio of Teff/ Treg (-Treg, no Treg cells).
Mean of triplicate assays from one of two experi-
ments shown.
Data are mean ± SEM and representative of the
analysis of at least three mice per genotype and
time point unless noted otherwise.the lung, liver, pancreas, and kidney, revealed large infiltrates of
mononuclear immune cells, especially in peri-vascular areas
(Figures 3C and 3D). Treg.Ezh2D/D mice had markedly reduced
life spans, eventually succumbing to the uncontrolled inflamma-
tion observed in all tissues examined (Figure 3E). Notably, we
observed similar defects in immune tolerance utilizing a different
Foxp3YFP-cre allele to delete Ezh2 specifically in Treg cells (data
not shown) (Rubtsov et al., 2008). This suggests that although
Ezh2-deficient Treg cells in Treg.Ezh2D/D mice are present at
normal to increased frequencies, appear grossly phenotypically
normal, and are functional in vitro, they are unable to properly
maintain immune homeostasis.
Impaired Immune Tolerance by Ezh2-Deficient Treg
Cells in Adult Mice
To determine whether mice with Ezh2-deficient Treg cells were
prone to autoimmunity due to an intrinsic defect in Treg cell func-Immunity 42, 227–238,tion, we utilized female mice heterozy-
gous for the Foxp3YFP-cre genetically tar-
geted allele. Due to the presence of
Foxp3 on the X chromosome and X-in-
activation, Foxp3YFP-cre/Foxp3WT;Ezh2fl/fl
females are chimeric, harboring both
wild-type and Ezh2-deficient Treg cells.
These females did not exhibit increased
T cell activation or any autoimmune
symptoms despite harboring equal fre-
quencies of Ezh2-deficient Treg cells as
mice with Ezh2D/+ Treg cells (Figures
S2E and S2F, and data not shown).
Thus, the disease in Treg.Ezh2D/D mice
is suppressed by the function of wild-type Treg cells, supporting a hypothesis that Ezh2-deficient
Treg cells are intrinsically defective.
Next we generated female mice that carried the Foxp3YFP-cre
and a Foxp3DTR allele, which expresses the diphtheria toxin re-
ceptor (DTR) under the control of the endogenous Foxp3 pro-
moter (Kim et al., 2007). By breeding Foxp3YFP-cre/Foxp3DTR
females with Ezh2fl alleles, we could selectively delete the wild-
type Treg cells expressing the Foxp3DTR allele by treatment
with diphtheria toxin (DT). This setting allowed us to acutely chal-
lenge Ezh2D/D Treg cells to maintain immune homeostasis in
adult mice (Figures 4A and S3A). As seen in Figure 4B, acute
depletion of wild-type Treg cells in mice harboring Ezh2D/D
Treg cells, as compared to mice with Ezh2D/+ Treg cells, led to
increased activation of both CD4+ and CD8+ T cells in lymph no-
des and the development of more severe pathology in these
mice (Figures S3B and S3C). In addition, the Ezh2D/D Treg cells
were reduced in frequency in the spleen and had a significantFebruary 17, 2015 ª2015 Elsevier Inc. 229
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B Figure 3. Ezh2 Deletion in Treg Cells Dis-
rupts Immune Homeostasis
(A and B) CD44 versus CD62L staining in CD4+
Foxp3 cells (A) and CD8+ cells (B) from peripheral
lymph nodes at 8 or 24 weeks of age.
(C) Representative H&E stained sections of lung,
liver, pancreas, and kidney from age-matched
Treg.Ezh2D/+ and Treg.Ezh2D/D mice (17 weeks
pictured). Scale bar represents 100 mM.
(D) Quantification of histological analysis from (C) of
mice aged 12–18 weeks old (n = 7–8 per genotype).
0–3 score: 0, no mononuclear infiltration; 3 high
degree of mononuclear infiltration (score 3 de-
picted in (C) for Treg.Ezh2D/D mice).
(E) Survival of Treg.Ezh2D/+ (n = 15) andTreg.Ezh2D/D
(n = 17) mice.
Data are mean ± SEM and representative of at least
three mice per genotype and age unless noted
otherwise. See also Figure S2.reduction in the expression of Foxp3 (Figures 4C–4E and S3D).
Therefore, Ezh2-deficient Treg cells could not prevent the activa-
tion of CD4+ and CD8+ T cells in vivo and this was associated
with a defect in Treg cell stability in the activated Treg cell pool.
Reduced Frequency and Increased Destabilization
of Treg Cells in Non-lymphoid Tissues of
Treg.Ezh2D/D Mice
We next examined Treg cells in non-lymphoid tissues. There
were massive reductions in the frequencies of Treg cells in
aged Treg.Ezh2D/D mice in all tissues examined (Figures 5A,
S4A, and S4B). Ezh2D/D Treg cells also exhibited lower Foxp3
expression in tissues based on Foxp3 reporter expression and
anti-FoxP3 antibody staining (Figures 5B and S4C), suggesting
that the autoimmune symptoms in Treg.Ezh2D/D were related to
a profound deficiency of Treg cells in the non-lymphoid tissues.
The origin and fate of the Treg cell lineagewith Ezh2-deficiency
was examined utilizing a lineage-tracing strategy by breeding
mice with an R26LSL-RFP allele to mice with the Foxp3-GFP-
hcre allele (Zhou et al., 2009). This allowed the tracking of newly
generated Treg cells (CD4+GFP+RFPneg cells), stable Treg cells230 Immunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc.(CD4+GFP+RFP+ cells), and cells that did
not maintain Foxp3 expression (CD4+
GFPnegRFP+ cells). Comparison of Tre-
g.Ezh2D/+ and Treg.Ezh2D/Dmice revealed
an increased proportion of GFP+RFPneg
cells in the thymus and lymph nodes of
Treg.Ezh2D/D mice, suggesting that Tre-
g.Ezh2D/D mice generate more new Treg
cells (Figure 5C). The GFP+RFPneg cells
were CD25+, Nrp-1+, and more naive
(CD44lo CD62Lhi) than GFP+RFP+ cells,
which suggests committed Treg cells of
thymic origin (Figures S4D and S4E)
(Miyao et al., 2012; Weiss et al., 2012; Ya-
dav et al., 2012). In addition, Treg.Ezh2D/D
mice had increased proportions of
GFPnegRFP+ cells across all tissues
analyzed (except for the thymus), indi-cating that Ezh2D/D Treg cells had a reduced capacity tomaintain
the stable Treg cell pool (CD4+GFP+RFP+ cells) (Figures 5C–5E).
Increased proportions of GFPnegRFP+ cells were also observed
in healthy Foxp3YFP-cre/Foxp3WT;Ezh2fl/fl females, indicating
that an impaired ability to maintain the Foxp3+ cell pool was
intrinsic to Ezh2D/D Treg cells and not just a byproduct of the
increased inflammation in Treg.Ezh2D/D mice (Figure S4F).
The highest percentages of GFPnegRFP+ cells were found in
non-lymphoid tissues (Figure 5E), where Treg cells appear highly
activated and showed decreased Foxp3 expression.While these
lineage-tracing experiments cannot distinguish whether Ezh2-
deficient Treg cells became destabilized early (GFP+RFPneg
cells) or late (GFP+RFP+ cells) after Foxp3 is expressed, recom-
bination of all the alleles, including both Ezh2fl alleles and the
R26LSL-RFP allele, would require the Foxp3-cre allele to be suffi-
ciently expressed (Miyao et al., 2012; Rubtsov et al., 2008). In
addition, the increased proportion of Foxp3 negative cells with
Ezh2-deficiency was restricted to the CD44hiCD62Llo population
with no significant increase in GFPnegRFP+ cells in the
CD44loCD62Lhi population (Figures S4G and S4H), suggesting
that Ezh2, which is induced in Treg cells after activation,
A C
D E
B
Figure 4. Acutely Challenged Ezh2-Deficient Treg Cells Are Unstable and Do Not Control T Cell Activation
(A) Experimental model to selectively deplete wild-type Treg cells to challenge Ezh2D/D Treg cells to maintain immune homeostasis.
(B) Analysis of CD4+ and CD8+ T cell activation in lymph nodes by CD44 and CD62L expression after four weeks of DT treatment (33/week) of Foxp3YFP-cre/
Foxp3DTR;Ezh2fl/+ or Foxp3YFP-cre/Foxp3DTR;Ezh2fl/fl mice.
(C andD) Representative flow cytometric analysis of the percentage of Foxp3+ Treg cells (of CD4+ cells) in spleens ofmice treatedwith DT (C) and quantification of
the percentage of Foxp3+ cells in the spleens or lymph nodes (D).
(E) MFI of Foxp3 expression by antibody staining of splenocytes of DT treated mice.
Data are mean ± SEM and representative of at least three mice per genotype from three independent experiments. See also Figure S3.promotes the maintenance of Foxp3 expression during Treg cell
responses.
Ezh2-Deficient Treg Cells Exhibit Altered Gene-
Expression Patterns after Activation
Gene-expression analysis (RNAseq) of CD62Lhi or CD62Llo
Ezh2D/+ and Ezh2D/D Treg cells (CD4+CD25+YFP+RFP+ cells)
sorted from lymph nodes and spleens of Foxp3YFP-cre/Foxp3WT;
Ezh2fl/+ or Foxp3YFP-cre/Foxp3WT;Ezh2fl/fl mice was performed
to investigate the underlying defects in Ezh2D/D Treg cells
following activation and/or differentiation (Figures S5A–5C).
Foxp3+ cells from chimeric female mice were used for this
analysis to identify alterations that precede Foxp3 protein
loss in mice that do not exhibit any inflammation-driven
abnormalities.
Principal component analysis revealed that the greatest dif-
ferences in gene expression patterns between Ezh2D/+ and
Ezh2D/D Treg cells occurred in the CD62Llo populations (Fig-
ure 6A), consistent with the hypothesis that defects in Ezh2D/D
Treg cells are manifested after activation. Next, we compared
the differentially expressed genes (DEGs) between CD62Llo
and CD62Lhi populations in Ezh2D/+ compared to Ezh2D/D Treg
cells to determine whether there were global differences in the
pattern of genes induced or repressed after activation (Fig-
ure 6B). Ezh2D/D Treg cells had dramatically increased expres-
sion of genes normally repressed in CD62Llo cells (lower left of
plot) as compared to a modest reduction in the expression of
genes normally induced in CD62Llo cells (upper right of plot).
To determine whether these changes in global gene repression
after activation resulted from decreased Ezh2-mediatedH3K27me3 deposition, we utilized the recently reported
H3K27me3 ChIP-seq dataset by Arvey et al. (2014) to identify
genes associated with increased deposition of H3K27me3
marks after Treg cell activation. As shown in Figure 6C, genes
associated with increasing H3K27me3 marks in activated Treg
cells were specifically enriched in the upregulated (or de-
repressed) DEGs in Ezh2D/D CD62Llo Treg cells (p < 7.8 3
108, K-S test). Furthermore, only the cumulative distribution
of the upregulated genes marked by H3K27me3 differed signif-
icantly (K-S test) from all DEGs (p < 1.95 3 109), whereas for
H3K27me3-marked, downregulated genes, there was no signif-
icant difference (p < 0.13). Thus, Ezh2, via H3K27me3 deposi-
tion, is required for the repressive gene program in Treg cells
after activation.
CD62Llo Ezh2-Deficient Treg Cells Are Similar to
Foxp3-Deficient Treg Cells
Analysis of the genes whose expression was dysregulated in
the absence of Ezh2 revealed a large number of ‘‘Treg cell
signature genes’’ (Figure 6B, red and blue text) (Hill et al.,
2007). Comparison of differentially expressed genes (DEGs)
between CD62Llo populations of Ezh2D/D versus Ezh2D/+ Treg
cells (termed Ezh2D/D) from our dataset to DEGs between
‘‘Foxp3gfpko’’ (cells with gfp inserted into the Foxp3 locus block-
ing Foxp3 protein expression) versus wild-type Treg cells
(termed Foxp3D) from a published dataset by Gavin et al.,
2007 revealed that Ezh2D/D Treg cells had global defects in
the Foxp3-mediated gene-expression program. Forty-one
percent of all DEGs in Ezh2D/D Treg cells were also differentially
expressed in Foxp3D Treg cells (Figure 6D). Furthermore, theImmunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc. 231
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B Figure 5. Reduced Frequency and Increased
Destabilization of Ezh2-Deficient Treg Cells
in Tissues
(A) Quantification of the frequency of Treg cells (as
percentage of Foxp3+ cells of CD4+ T cells) from
indicated tissues of age-matched mice 18 to
30 weeks old.
(B) Representative Foxp3-GFP reporter expression
by flow cytometry of CD4+CD25+ populations from
the skin and lung of indicated mice.
(C and D) Representative lineage tracing of Treg
cells in Treg.Ezh2D/+ and Treg.Ezh2D/Dmice by flow
cytometry of thymus and lymph nodes (C) or lymph
nodes and lung (D). Cells depicted are gated CD4+.
Mice depicted were 17 to 18 weeks old.
(E) Quantification of the percentage of GFPneg.RFP+
cells (of all CD4+RFP+ cells) across indicated tis-
sues of Treg.Ezh2D/+ and Treg.Ezh2D/D mice. f, no
T cells detected.
Data are mean ± SEM and representative of at least
three mice per genotype from at least three inde-
pendent experiments. See also Figure S4.qualitative changes in the expression patterns of the shared
genes were similar (Figure 6E). Gene set enrichment analysis
showed that the expression pattern of Ezh2D/D Treg cells
more closely resembled conventional CD4+ T than Treg cells
(Figure S5D). Finally, as shown in Figure 6E, many of the over-
lapping genes were direct Foxp3 targets based on published
data of chromatin immunoprecipitation for Foxp3 (Samstein
et al., 2012). In fact, when limiting the DEGs from the two data-
sets to only Foxp3-bound genes, 58.8% of all DEGs in Ezh2D/D
Treg cells overlapped with DEGs from Foxp3D Treg cells, thus
dramatically enriching the overlap in these two datasets (Fig-
ures 6F and S5E). These overlapping DEGs were represented
among both up- and downregulated genes in both datasets.
However, the upregulated (or de-repressed) genes in Foxp3D
and Ezh2D/D Treg cells were enriched two-fold in H3K27me3
marks that are increased upon Treg cell activation (22.3%,
red from Arvey et al. [2014]) versus the coordinately downregu-232 Immunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc.lated genes (10.3%, blue) (Figures 6F and
S5F). These results suggest an essential
role for Ezh2 in promoting the Foxp3-
dependent Treg cell program during acti-
vation and are consistent with the model
proposed by Arvey et al. (2014) that
a number of Foxp3-bound genes are
repressed by Ezh2-mediated H3K27 tri-
methylation in activated Treg cells. There
was also an overlap of Foxp3-bound
and downregulated genes in Foxp3D
and Ezh2D/D Treg cells (i.e., genes weakly
induced in Ezh2D/D Treg cells upon
activation) that were less enriched in
activation-associated H3K27me3 marks
(Figures 6F). This may suggest that Ezh2
promotes the expression of a subset
of genes bound by Foxp3, possibly
in a PRC2-independent manner, as
described in the context of cancer (Xuet al., 2012), although downregulation of these genes could
also be an indirect result of Ezh2 deficiency in these cells.
Inability of Ezh2-Deficient Treg Cells to Control
Remission in Experimental Autoimmune
Encephalomyelitis
To determine the acute clinical impact of Ezh2-deficiency in Treg
cells, we examined Ezh2D/D Treg cell phenotypes in experimental
autoimmune encephalomyelitis (EAE), an inducible mouse
model of multiple sclerosis. As seen in Figure 7A, immunization
of Treg.Ezh2D/+ (or Ezh2+/+) mice with the neural antigen myelin
oligodendrocyte glycoprotein (MOG35–55 peptide), resulted in
moderate disease, with 52% of the mice achieving the highest
clinical disease score of 4. In contrast, 90% of Treg.Ezh2D/D
mice exhibited the most severe form of the disease. Further-
more, while all Treg.Ezh2D/+ mice ultimately regained hind limb
mobility, none of the Treg.Ezh2D/D mice recovered from the
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Figure 6. Ezh2 Is Required in Activated Treg Cells to Stabilize the Foxp3-Driven Treg Program
(A) Principal-component analysis of the transcriptomes of sorted CD62Lhi and CD62Llo YFP+ Treg cells from lymph nodes and spleens of female Foxp3YFP-cre/
Foxp3WT;Ezh2fl/+ (Ezh2D/+) and Foxp3YFP-cre/Foxp3WT;Ezh2fl/fl (Ezh2D/D) mice. The contribution of each principal component to the total variance in the data is
shown on each axes (%). Each point represents the combined average of three biological samples except for CD62Lhi Ezh2D/+, which is from two samples.
(B) Comparison of all differentially expressed genes (DEGs = 3097, FDR < 0.05) between CD62Lhi and CD62Llo Treg cells in the absence of Ezh2 (Ezh2D/D, y axis)
or presence of Ezh2 (Ezh2D/+, x axis). Dashed line represents the trend of all genes differentially regulated between the Ezh2D/D and Ezh2D/+ datasets. Data points
are colored by significant differences in gene expression between the CD62Llo populations of Ezh2D/D versus Ezh2D/+ Treg cells: red, increased expression; blue,
reduced expression. Differentially expressed ‘‘Treg cell signature’’ genes are labeled and colored with respect to expression change.
(C) Cumulative distribution of fold changes in all DEGs (black dotted line, 3097 genes) or DEGswith increased H3K27me3marks in activated Treg cells (green line,
465 genes) between CD62Llo Ezh2D/D and Ezh2D/+ Treg cells, p < 7.8 3 108 using the two-sample Kolmogorov-Smirnov (K-S) statistical test.
(D) Venn diagram of DEGs shared between Foxp3D Treg cells (Foxp3gfpkoTreg versus WT Treg: 1,678 genes) and activated Ezh2D/D Treg cells (CD62Llo Ezh2D/D
versus CD62Llo Ezh2D/+ Treg cells: 831 genes).
(E) Clustering of all genes up or down (341 DEGs, FDR < 0.05) between Foxp3D and Ezh2D/D data sets (left) and expression of Foxp3-bound genes that are up- or
downregulatedR0.5 log2 fold change (right). *, genes also identified by GSEA of Ezh2
D/D Treg cells compared to Treg versus Tconv immunological signatures.
(F) Left to right: Venn diagram depicting Foxp3-bound DEGs in-common between Foxp3D and Ezh2D/D Treg cells (left); overlap in Foxp3-bound DEGs either up-
(top) or downregulated (bottom) in both datasets (middle); percentage of shared up- (top) or downregulated Foxp3-bound DEGs (bottom) in Foxp3D and Ezh2D/D
that are associated with increased H3K27me3 marks in activated versus resting WT Treg cells (right).
See also Figure S5.disease. There was a reduction in Treg cell frequency, as well as
an increased percentage of GFPnegRFP+ cells, specifically in the
CNS tissues of Treg.Ezh2D/Dmice (Figures 7B and 7C). These re-
sults recapitulated the phenotypes observed spontaneously in
Treg.Ezh2D/D mice. Importantly, Ezh2D/D Treg cells displayed
the same defective phenotypes in a competitive environment
with wild-type Treg cells in Foxp3YFP-cre/Foxp3WT female mice
with EAE (Figures S6A and S6B). However, female Foxp3YFP-cre/Foxp3WT;Ezh2fl/fl mice recovered from the disease (Figure S6C),
strongly suggesting that Ezh2 deficiency renders Treg cells
intrinsically defective in regulating tissue inflammation.
The EAE system allowed us to follow newly activated, antigen-
specific Treg cells over time utilizing I-Ab tetramers loaded with
MOG38–49 peptide.MOG-specific Ezh2
D/D Treg cells were readily
detectable in the draining lymph node 8 days after EAE induc-
tion, indicative of an expansion of these cells, which are nearlyImmunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc. 233
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Figure 7. Mice with Ezh2-Deficient Treg Cells Do Not Resolve EAE-Induced Tissue Inflammation
(A) Plot of clinical score versus time (days) after induction of EAE in indicated mice. Inset shows percentage of mice with score 4 disease. Mean cumulative data
from three experiments.
(B and C) Percentage of Foxp3+ cells (of CD4+ T cells, B) or GFPneg.RFP+ cells (of CD4+RFP+ cells, C) in draining lymph nodes (dLN) or central nervous system
tissues (CNS) at peak disease (18–27 days after EAE induction). Data pooled from three independent experiments.
(D) Representative analysis of CD4+ T cells from dLN enriched and stained with MOG38–49-I-A
b tetramers from unprimed control mice (left plot) or mice primed
with MOG35–55+CFA eight days earlier (middle plots) and the fraction of Foxp3-gfp
+ cells of the total MOG-I-Ab+ cells from dLN (right plots).
(E) Quantification of the percentage of Foxp3-gfp+ cells of all MOG-I-Ab+ cells in enriched dLN from (D).
(F) Representative analysis of CD4+ T cells from CNS stained with CD44 and CLIP-I-Ab (neg. ctrl, left plots) or MOG38–49-I-A
b tetramers (middle plots) and the
fraction of Foxp3-gfp+ cells of the total MOG-I-Ab+ cells from CNS (right plots).
(G) Quantification of the percentage of Foxp3-gfp+ cells of all MOG-I-Ab+ cells in CNS.
(H) MFI of Foxp3 expression by GFP reporter in dLN of indicated mice 8 days after EAE induction.
Data are mean ± SEM and representative of at least three mice per genotype from at least three independent experiments. See also Figures S6 and S7.undetectable in unprimed mice (Figure 7D) (Bailey-Bucktrout
et al., 2013). However, the frequency of MOG-specific Treg cells
(as a fraction of all MOG-specific CD4+ T cells) was reduced as234 Immunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc.compared to controls (Figures 7D and 7E), especially in the
CNS tissues at the peak of disease (Figures 7F and 7G). To
directly assess whether Ezh2D/D Treg cells were activated and
proliferated normally in response to antigenic stimulation in vivo,
we labeled 2D2 T cell receptor (TCR) transgenic (MOG35–55-spe-
cific) Ezh2D/+ and Ezh2D/D Treg cells with CFSE and co-trans-
ferred the cells into MOG-primed wild-type mice (Bettelli et al.,
2003). Four days after transfer, both Ezh2D/+ and Ezh2D/D
MOG-specific Treg cells had divided to a similar extent (Fig-
ure S7A). Similarly, the activation and proliferation of Ezh2D/D
Treg cells in vitro was intact (Figure S7B); however, Ezh2D/D
Treg cells did exhibit increased apoptosis following several
rounds of division (Figures S7C and S7D). Finally, the newly
activated MOG-specific Treg cells exhibited reduced Foxp3
expression (Figure 7H), suggesting that Ezh2D/D Treg cells are
destabilized early after activation, driving reduced frequencies
of Treg cells in tissues. These results support the conclusion
that deletion of Ezh2 in Treg cells leads to a selective loss of an-
tigen-specific activated cells at the site of inflammation leading
to uncontrolled autoimmunity.
DISCUSSION
While the role of the polycomb genes in maintaining cellular fate
decisions during development is established, their role in main-
taining the identity of mature, differentiated cells after cellular
activation is less clear. In this study, we identified Ezh2 as an
epigenetic modifier induced by CD28 co-stimulation that is
necessary for the maintenance of Treg cell identity after activa-
tion. Mice with Ezh2-deficient Treg cells failed to maintain im-
mune tolerance, developed multi-organ autoimmunity, and
were incapable of resolving inflammation in CNS tissues upon
acute induction of autoimmunity (EAE). These mice exhibited re-
ductions in Treg cells specifically in the non-lymphoid tissues,
suggesting that Ezh2-deficiency selectively disrupts the acti-
vated Treg cell pool. Comparative gene-expression analysis of
activated (CD62Llo) versus quiescent (CD62Lhi) Treg cells from
healthy mice confirmed that the activated Ezh2-deficient Treg
cells had aberrant expression of the Foxp3-dependent gene-
expression program, including many Treg cell signature genes
that were direct targets of Foxp3 and were de-repressed.
Furthermore, Ezh2-deficient Treg cells, despite expressing
Foxp3, had a gene-expression pattern that resembled Foxp3-
deficient Treg cells and exhibited lineage instability after activa-
tion. These results reveal an important role for CD28-induced
epigenetic control in the differentiation and maintenance of re-
sponding Treg cells and highlight the importance of chromatin
regulation in the maintenance of immune homeostasis particu-
larly in non-lymphoid tissues.
Epigenetic mechanisms that alter chromatin organization are
thought to control, or at least reinforce, the differentiation and
maintenance of polarized T helper cell subsets (Ansel et al.,
2003; Wilson et al., 2009). Deletion of Ezh2 in CD4+ T cells was
recently shown to promote the capacity of in vitro differentiated
T helper subsets to convert to opposing phenotypes; however, a
role for this chromatin modifier in Treg cells was not elucidated
(Tumes et al., 2013). Treg cells harbor a unique constellation of
epigenetic histone modifications compared to other T cell sub-
sets (Wei et al., 2009), yet the molecules and mechanisms that
regulate these distinctions are less clear. Recent studies indicate
that the unique epigenetic state in Treg cells might be indepen-
dent of their lineage-specifying transcription factor Foxp3 anddepend on signals from the T cell receptor and co-stimulatory
pathways to alter the chromatin accessibility of key Treg-cell-ex-
pressed genes (Ohkura et al., 2012; Samstein et al., 2012).
Hence, it is noteworthy that we identified Ezh2 as a chromatin
modifier dependent on CD28 co-stimulation.
Ezh2-deficient Treg cells emigrating from the thymus ap-
peared phenotypically normal and functional and were even
increased in Treg.Ezh2D/D mice. Importantly, Ezh2 was only
deleted subsequent to Foxp3 expression in this model, thus
confining our analysis to the effects of Ezh2 deletion in estab-
lished Treg cells and excluding its role in the development of
the Treg cell lineage. In this context, Ezh2-deficient Treg cells ex-
hibited altered transcription and destabilization only after they
were activated. During CD4+ T cell activation, cellular prolifera-
tion is accompanied by coordinated changes in chromatin struc-
ture that are linked to the differentiation of divergent types of T
helper cells (Agarwal and Rao, 1998; Bird et al., 1998; Grogan
et al., 2001). Treg cells exit the thymus in a relatively naive state
and upon peripheral activation, differentiate to tailor their sup-
pressive activity to the particular inflammatory environment
they will control (Campbell and Koch, 2011; Darrasse-Je`ze
et al., 2009; Fisson et al., 2003; Rosenblum et al., 2011). A recent
study indicated that TCR stimulation alone is insufficient to drive
the differentiation of Treg cells from a naive-like to effector-like
state and that additional inflammatory stimuli are required, pre-
sumably to induce the expression of co-stimulatory molecules
like B7-1 andB7-2 on antigen-presenting dendritic cells that pro-
vide additional signals with TCR stimulation (Smigiel et al., 2014).
Therefore, a stepwise connection between CD28-dependent
activation in lymphoid tissues, differentiation into effector-like
Treg cells, and ultimately the migration and function of these
Treg cells in non-lymphoid tissues seems probable.
From this perspective, the paucity of Ezh2-deficient Treg cells
specifically in non-lymphoid tissues would be expected if these
Treg cells were destabilized after activation, before their migra-
tion to target tissues. Indeed, induction of EAE in Treg.Ezh2D/D
mice generated greatly reduced Treg frequencies in the CNS
and, as a result, these mice never resolved the inflammation in
the CNS. However, the induction of disease in Treg.Ezh2D/D
mice was not accelerated, likely because Ezh2-deficient Treg
cells were activated and proliferated normally at the earliest
time points after priming (and were suppressive in vitro) but
showed signs of Foxp3 destabilization and Treg cell loss at later
time points. Together, these data indicate that Ezh2-deficient
Treg cells become defective subsequent to activation and this
is consistent with our gene-expression analysis showing tran-
scriptional divergence specifically in the activated (CD62Llo)
Treg cell pool. The data also suggest that different subsets of
Treg cells might be specialized for controlling different stages
of disease, with naive Treg cells beingmost important to the con-
trol of initial priming events in lymph nodes and activated effector
Treg cells being most important to the resolution of inflammation
at the site of tissue destruction.
We found that Ezh2 functions largely to repress genes after
cellular activation in Treg cells. This is consistent with the known
epigenetic activity of Ezh2 but also might suggest a specific role
for gene repression upon activation in Treg cells. Indeed, Foxp3
directly binds many genes exhibiting increased expression
in activated Ezh2-deficient Treg cells. Several studies haveImmunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc. 235
reported that Foxp3 acts predominantly as a repressor upon
activation of Treg cells (Arvey et al., 2014; Marson et al., 2007;
Morikawa et al., 2014). This might serve to preserve the Treg-
specific gene expression program by dampening the induction
of genes normally upregulated during T cell activation. Foxp3
might exert this repression by recruiting the Ezh2-containing
polycomb repressive complex to key targets during activa-
tion, because Foxp3 repressed genes are associated with
H3K27me3 deposition and reduced chromatin accessibility (Ar-
vey et al., 2014). By genetically ablating Ezh2 in Treg cells in this
study, we have functionally validated the importance of Ezh2 ac-
tivity in activated Treg cell stability and function. We hypothesize
that Ezh2, in collaboration with Foxp3, is responsible for control-
ling an entire network of genes essential for the Treg cell tran-
scriptional program during activation and that the dysregulation
of many genes ultimately drives the phenotypes observed in
Ezh2-deficient Treg cells. Among this set of co-regulated genes
that are upregulated in Ezh2-deficient Treg cells and normally
enriched in H3K27me3 marks with activation are several genes
that are known to antagonize Treg cell function (e.g., Pde3b,
Tcf7, Lef1) (Gavin et al., 2007; Keerthivasan et al., 2014). Impor-
tantly, while our conclusions from the comparison of H3K27me3
marks in wild-type Treg cells to de-repressed genes in Ezh2-
deficient Treg cells are consistent with a direct role for Ezh2-
mediated H3K27me3marks supporting a Treg cell gene-expres-
sion program, only an assessment of the changes to H3K27me3
marks in Ezh2-deficient cells would provide direct evidence of
this mechanism. Thus, we cannot rule out that indirect effects
of Ezh2 deficiency, unrelated to its role in H3K27 tri-methylation
specifically in Treg cells, might contribute to the phenotypes
observed.
In this study, we have demonstrated that the epigenetic regu-
lator, Ezh2, can coordinate cellular activation and the mainte-
nance of cellular identity. Ezh2 bridges these processes by
directly responding to extracellular cues that drive proliferation
(CD28 co-stimulation) and functioning with lineage specifying
transcription factors (Foxp3) to reinforce the cells’ transcriptional
program. In the context of the adaptive immune system, where
the activation and expansion of subsets of cells with unique
specificities is essential, epigenetic regulation of the fidelity of
cell identity is paramount. With the recent development of
several drugs that target specific chromatin modifiers, new op-
portunities might exist to modulate the cellular identity of im-
mune cells, namely Treg cells, for therapeutic benefit.
EXPERIMENTAL PROCEDURES
Mice
All mice used were bred onto a C57BL/6 background a minimum of five gen-
erations. All mouse experiments (or cells from mice of given genotypes) used
comparisons between littermates or age-matched control mice. CD28fl mice
harbor loxP sites flanking the extracellular and transmembrane domains of
Cd28 (exons 2–3) (Zhang et al., 2013). Foxp3-GFP-hcre and Foxp3YFP-cre
mice express Cre recombinase in Foxp3+ cells utilizing distinct technologies
(Rubtsov et al., 2008; Zhou et al., 2008). Ezh2fl mice harbor loxP sites flanking
exons 16–19 encoding the SET domain (Su et al., 2003). For diphtheria toxin
treatments, mice were treated with a dose of 50 mg/kg three times per week,
every other day. For EAE studies, disease was induced as described previ-
ously (Bailey-Bucktrout et al., 2013) and clinical disease was scored by
ascending hind-limb paralysis as follows: 1, paralysis of tail; 2, hind limb weak-
ness; 3, paralysis of one hind limb; 4, paralysis of both hind-limbs. Mice were236 Immunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc.monitored at least 6 days for recovery after reaching score 4 disease. All ex-
periments were done according to the Institutional Animal Care and Use Com-
mittee guidelines of the University of California, San Francisco.
Lymphocyte Isolation
Cells from lymphoid organs were prepared by mechanical disruption between
frosted slides or from non-lymphoid organs by digestion in RPMI supple-
mented with HEPES and 20 mg/ml DNase I (Roche) with these modifications:
lungs and liver were prepared by mincing and digesting the tissues for 1 hr
at 37C with 125 U/ml Collagenase D (Roche); whole pancreas was prepared
by digesting for 30min at 37Cwith 0.8 mg/ml Collagenase P (Roche) followed
by mincing; skin was prepared from the trunk skin between limbs, removing
hair and subcutaneous fat, and digesting for 45 min at 37C with 2 mg/ml
Collagenase XI (Sigma) and 0.5 mg/ml Hyaluronidase (Sigma). All suspensions
were passaged over 40 mm filters before cell staining or activation. Isolation of
lymphocytes from the spinal cord and cerebellum (CNS) of mice with EAE was
done as described (Bailey-Bucktrout et al., 2013).
CD4 Enrichment, Cell Sorting, and Flow Cytometry
CD4+ T cells were enriched for western analyses by negative selection using
EasySep magnetic bead kit (STEMCELL Technologies) prior to activation
(with simultaneous depletion of CD25+ cells) or 24 hr after mixed lymphocyte
activation. All other purified populations (confirmed R95%) were obtained
by sorting single cells usingMoFlo (BeckmanCoulter) or FACSAria (BD-Biosci-
ences) machines. Utilizing Foxp3-driven GFP (or YFP) expression in combina-
tion with antibody staining for CD8a (53-6.7), CD4 (GK1.5), CD25 (PC61), and
CD62L (MEL-14), naive CD4+ T cells (CD4+CD62L+CD8GFPCD25) and
Treg cells (CD4+GFP+CD25+CD62L+/CD8) were sorted. When available,
the Cre-activated R26LSL-RFP reporter was also used. Live cells were stained
with antibodies to extracellular antigens for 20–30 min on ice and then fixed
and permeabilized (eBiosciences) for staining of intracellular antigens. Flow
cytometry was performed on LSR II machines (BD Biosciences) and analyzed
with Flowjo software (Tree Star).
MHCII Tetramer Staining
Draining lymph nodes (inguinal, brachial, and axillary) or CNS-infiltrating cells
from mice immunized with MOG+CFA were stained with MOG38–49-I-A
b-APC
tetramer (or CLIP-I-Ab-APC, CNS only) for 2 hr at room temperature, followed
by staining with other antibodies on ice. For dLN cells, tetramer-positive cells
were first enriched using anti-APC microbeads and MACS LS separation col-
umns (Miltenyi Biotec). Tetramers provided by the National Institutes of Health
Tetramer Core.
In Vitro Stimulation and Proliferation
Cells were activated with anti-CD3 and anti-CD28 coated beads (Dynabeads
Mouse T-Activator CD3/CD28, Invitrogen) at a ratio of 1:1 (cell:bead), beads
coated selectively with anti-CD3 or anti-CD3 and anti-CD28 (T Cell Activa-
tion/Expansion Kit mouse, Miltenyi Biotec), or 1 mg/ml soluble antibodies
against CD3 (clone 145-2C11) ± CD28 (clone PV-1). Cells were kept at a con-
centration of 106 cells/ml in RPMI medium supplemented with 10% FBS,
non-essential amino acids, sodium pyruvate, L-glutamine, HEPES, and
b-ME, and cells cultured more than 24 hr were supplemented with 200–
2,000 IU/ml recombinant human IL-2 (Chiron Corp). To monitor proliferation,
we labeled sorted cells with CFSE or Cell Trace Violet (CTV, Invitrogen).
In vitro Treg cell suppression was performed by labeling naive CD4+
T cells with CTV in the presence of 1 mg/ml anti-CD3 antibody (clone 145-
2C11), irradiated splenocytes (from TCRa-deficient mice), and different ratios
of Treg cells. The percentage of undivided cells (no dilution of CTV) was
analyzed 3 days later.
RNA Isolation and qPCR
RNA was isolated by TRIzol homogenization and extraction (Invitrogen). For
qPCR of Ezh2 transcripts, RNA was converted to cDNA using SuperScript III
First-Strand Synthesis (Invitrogen), and measured using Taqman probe
Mm00468464 (Life Technologies) with Taqman Fast Universal mix or the
primers 50-GCAGGGACTGAAACTGGGGGAG (forward) and 50- CAGCAC
CACTCCACTCCACATTC (reverse) with Fast SYBR PCR master mix (Applied
Biosystems). Samples were run in duplicate or triplicate on the Applied
Biosystems 7500/7900 Fast Real-Time PCR System and normalized to HPRT
or 18S RNA.
Western Blotting
Cells were lysed at a concentration 106 cells/50 ml of RIPA lysis buffer
(50 mM Tris-HCl pH7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
0.1% SDS, 0.5% DOC, 1 mM DTT) with protease inhibitor cocktail (Sigma)
and PhosSTOP (Roche), separated on a NuPAGE Novex 4%–12% Bis-Tris
Gel (Invitrogen), transferred to PVDF membranes, stained with anti-Ezh2
monoclonal antibody (D2C9, Cell Signaling Technology) or anti-Actin poly-
clonal antibody (Sigma) followed by anti–rabbit IgG-HRP (GE Healthcare),
and detected with SuperSignal West Femto Substrate (Thermo Scientfic) on
film (Kodak).
Histology
Tissues fixed in 10% formalin overnight, preserved in 70% EtOH, and
embedded in paraffin were cut and sections stained with hematoxylin and
eosin (H&E). Infiltrate scoring was performed by blinded assessment of at least
three sections of each tissue per mouse.
Transcriptome Analysis and Bioinformatics
RNA extracted from sorted populations Ezh2D/D CD62Lhi, Ezh2D/D CD62Llo,
Ezh2D/+ CD62Lhi, and Ezh2D/+ CD62Llo Treg cells (n = 3 biological samples/
group, except Ezh2D/+ CD62Lhi, n = 2) underwent RNA sequencing (RNAseq)
at the UCSF Sandler Asthma Basic Research Center Functional Genomics
Core using the Illumina HiSeq SE 50bp platform. Detailed methods for
RNAseq, microarray, GSEA, and genome-wide binding site analyses are
provided in the Supplemental Information.
Statistics and Statistical Analysis
Statistical tests used for bioinformatics analysis were described in methods or
legends. p values from unpaired two-tailed Student’s t tests were used for all
other statistical comparisons between two groups and data were displayed as
the mean ± SEM. p values are denoted in figures by: *, p < 0.05; **, p < 0.01;
***, p < 0.001.
ACCESSION NUMBERS
The GEO accession number for the RNA-seq data reported in this paper is
GSE58998.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2015.01.007.
AUTHOR CONTRIBUTIONS
M.D. and J.A.B. designed the study; M.D. performed all experiments with
assistance from J.Q., W.L.R., M.M.M., D.H., R.Z., and L.T.; G.C. performed
bioinformatic analyses; A.M. provided conceptual advice; M.D. and J.A.B.
wrote the manuscript.
ACKNOWLEDGMENTS
We thank D. Erle, A. Barczak, R. Barbeau, and J. Pollack of the UCSF Sandler
Center Functional Genomics Core for assistance with RNAseq data; M. Lee, V.
Nguyen, N. Lescano, and J. Paw for assisting with flow cytometry; K. Fasano
for preparation of tissues for histological analyses; N. Ali andM. Rosenblum for
assistance with harvesting cells from mouse skin; and A. Abbas, M.S. Ander-
son, F. van Gool, S.A. Villalta, and A.G. DuPage for critical reading of this
manuscript. This work was supported by NIH grants R01 AI046643 and UM1
AI-12-059. G.C. was supported by a JDRF fellowship. M.D. was supported
by the Helen Hay Whitney Foundation and NIH T32 grant to UCSF
(A1007334-23A1). J.A.B. is the A.W. andMaryMargaret ClausenDistinguished
Professor in Metabolism and Endocrinology.Received: September 29, 2014
Revised: December 5, 2014
Accepted: January 22, 2015
Published: February 10, 2015
REFERENCES
Agarwal, S., and Rao, A. (1998). Modulation of chromatin structure regulates
cytokine gene expression during T cell differentiation. Immunity 9, 765–775.
Ansel, K.M., Lee, D.U., and Rao, A. (2003). An epigenetic view of helper T cell
differentiation. Nat. Immunol. 4, 616–623.
Arvey, A., van der Veeken, J., Samstein, R.M., Feng, Y., Stamatoyannopoulos,
J.A., and Rudensky, A.Y. (2014). Inflammation-induced repression of chro-
matin bound by the transcription factor Foxp3 in regulatory T cells. Nat.
Immunol. 15, 580–587.
Bailey-Bucktrout, S.L., Martinez-Llordella, M., Zhou, X., Anthony, B.,
Rosenthal, W., Luche, H., Fehling, H.J., and Bluestone, J.A. (2013). Self-anti-
gen-driven activation induces instability of regulatory T cells during an inflam-
matory autoimmune response. Immunity 39, 949–962.
Bettelli, E., Pagany, M., Weiner, H.L., Linington, C., Sobel, R.A., and Kuchroo,
V.K. (2003). Myelin oligodendrocyte glycoprotein-specific T cell receptor
transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp.
Med. 197, 1073–1081.
Bird, J.J., Brown, D.R., Mullen, A.C., Moskowitz, N.H., Mahowald, M.A., Sider,
J.R., Gajewski, T.F., Wang, C.R., and Reiner, S.L. (1998). Helper T cell differ-
entiation is controlled by the cell cycle. Immunity 9, 229–237.
Campbell, D.J., and Koch, M.A. (2011). Phenotypical and functional speciali-
zation of FOXP3+ regulatory T cells. Nat. Rev. Immunol. 11, 119–130.
Chang, S., and Aune, T.M. (2007). Dynamic changes in histone-methylation
‘marks’ across the locus encoding interferon-gamma during the differentiation
of T helper type 2 cells. Nat. Immunol. 8, 723–731.
Darrasse-Je`ze, G., Deroubaix, S., Mouquet, H., Victora, G.D., Eisenreich, T.,
Yao, K.H., Masilamani, R.F., Dustin, M.L., Rudensky, A., Liu, K., and
Nussenzweig, M.C. (2009). Feedback control of regulatory T cell homeostasis
by dendritic cells in vivo. J. Exp. Med. 206, 1853–1862.
Fisson, S., Darrasse-Je`ze, G., Litvinova, E., Septier, F., Klatzmann, D., Liblau,
R., and Salomon, B.L. (2003). Continuous activation of autoreactive CD4+
CD25+ regulatory T cells in the steady state. J. Exp. Med. 198, 737–746.
Gavin, M.A., Rasmussen, J.P., Fontenot, J.D., Vasta, V., Manganiello, V.C.,
Beavo, J.A., and Rudensky, A.Y. (2007). Foxp3-dependent programme of reg-
ulatory T-cell differentiation. Nature 445, 771–775.
Grogan, J.L., Mohrs, M., Harmon, B., Lacy, D.A., Sedat, J.W., and Locksley,
R.M. (2001). Early transcription and silencing of cytokine genes underlie polar-
ization of T helper cell subsets. Immunity 14, 205–215.
Hill, J.A., Feuerer, M., Tash, K., Haxhinasto, S., Perez, J., Melamed, R., Mathis,
D., and Benoist, C. (2007). Foxp3 transcription-factor-dependent and -inde-
pendent regulation of the regulatory T cell transcriptional signature.
Immunity 27, 786–800.
Jacob, E., Hod-Dvorai, R., Schif-Zuck, S., and Avni, O. (2008). Unconventional
association of the polycomb group proteins with cytokine genes in differenti-
ated T helper cells. J. Biol. Chem. 283, 13471–13481.
Keerthivasan, S., Aghajani, K., Dose, M., Molinero, L., Khan, M.W.,
Venkateswaran, V., Weber, C., Emmanuel, A.O., Sun, T., Bentrem, D.J.,
et al. (2014). beta-Catenin promotes colitis and colon cancer through
imprinting of proinflammatory properties in T cells. Sci Transl Med 6, 225ra228.
Kim, J.M., Rasmussen, J.P., and Rudensky, A.Y. (2007). Regulatory T cells
prevent catastrophic autoimmunity throughout the lifespan of mice. Nat.
Immunol. 8, 191–197.
Koyanagi, M., Baguet, A., Martens, J., Margueron, R., Jenuwein, T., and Bix,
M. (2005). EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and
Il13 gene silencing in Th1 cells. J. Biol. Chem. 280, 31470–31477.
Lenschow, D.J., Herold, K.C., Rhee, L., Patel, B., Koons, A., Qin, H.Y., Fuchs,
E., Singh, B., Thompson, C.B., and Bluestone, J.A. (1996). CD28/B7 regulationImmunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc. 237
of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity
5, 285–293.
Mandal, M., Powers, S.E., Maienschein-Cline, M., Bartom, E.T., Hamel, K.M.,
Kee, B.L., Dinner, A.R., and Clark, M.R. (2011). Epigenetic repression of the Igk
locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2.
Nat. Immunol. 12, 1212–1220.
Margueron, R., and Reinberg, D. (2011). The Polycomb complex PRC2 and its
mark in life. Nature 469, 343–349.
Marson, A., Kretschmer, K., Frampton, G.M., Jacobsen, E.S., Polansky, J.K.,
MacIsaac, K.D., Levine, S.S., Fraenkel, E., von Boehmer, H., and Young, R.A.
(2007). Foxp3 occupancy and regulation of key target genes during T-cell stim-
ulation. Nature 445, 931–935.
Martı´nez-Llordella, M., Esensten, J.H., Bailey-Bucktrout, S.L., Lipsky, R.H.,
Marini, A., Chen, J., Mughal, M., Mattson, M.P., Taub, D.D., and Bluestone,
J.A. (2013). CD28-inducible transcription factor DEC1 is required for efficient
autoreactive CD4+ T cell response. J. Exp. Med. 210, 1603–1619.
Miyao, T., Floess, S., Setoguchi, R., Luche, H., Fehling, H.J., Waldmann, H.,
Huehn, J., and Hori, S. (2012). Plasticity of Foxp3(+) T cells reflects promiscu-
ous Foxp3 expression in conventional T cells but not reprogramming of regu-
latory T cells. Immunity 36, 262–275.
Morikawa, H., Ohkura, N., Vandenbon, A., Itoh,M., Nagao-Sato, S., Kawaji, H.,
Lassmann, T., Carninci, P., Hayashizaki, Y., Forrest, A.R., et al.; FANTOM
Consortium (2014). Differential roles of epigenetic changes and Foxp3 expres-
sion in regulatory T cell-specific transcriptional regulation. Proc. Natl. Acad.
Sci. USA 111, 5289–5294.
Ohkura, N., Hamaguchi, M., Morikawa, H., Sugimura, K., Tanaka, A., Ito, Y.,
Osaki, M., Tanaka, Y., Yamashita, R., Nakano, N., et al. (2012). T cell receptor
stimulation-induced epigenetic changes and Foxp3 expression are indepen-
dent and complementary events required for Treg cell development.
Immunity 37, 785–799.
Pierson, W., Cauwe, B., Policheni, A., Schlenner, S.M., Franckaert, D., Berges,
J., Humblet-Baron, S., Scho¨nefeldt, S., Herold, M.J., Hildeman, D., et al.
(2013). Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity
of Foxp3+ regulatory T cells. Nat. Immunol. 14, 959–965.
Raaphorst, F.M., Otte, A.P., van Kemenade, F.J., Blokzijl, T., Fieret, E., Hamer,
K.M., Satijn, D.P.E., and Meijer, C.J.L.M. (2001). Distinct BMI-1 and EZH2
expression patterns in thymocytes and mature T cells suggest a role for
Polycomb genes in human T cell differentiation. J. Immunol. 166, 5925–5934.
Rosenblum, M.D., Gratz, I.K., Paw, J.S., Lee, K., Marshak-Rothstein, A., and
Abbas, A.K. (2011). Response to self antigen imprints regulatory memory in tis-
sues. Nature 480, 538–542.
Rubtsov, Y.P., Rasmussen, J.P., Chi, E.Y., Fontenot, J., Castelli, L., Ye, X.,
Treuting, P., Siewe, L., Roers, A., Henderson, W.R., Jr., et al. (2008).
Regulatory T cell-derived interleukin-10 limits inflammation at environmental
interfaces. Immunity 28, 546–558.
Salomon, B., Lenschow, D.J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A.,
and Bluestone, J.A. (2000). B7/CD28 costimulation is essential for the homeo-
stasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune
diabetes. Immunity 12, 431–440.
Samstein, R.M., Arvey, A., Josefowicz, S.Z., Peng, X., Reynolds, A.,
Sandstrom, R., Neph, S., Sabo, P., Kim, J.M., Liao, W., et al. (2012). Foxp3 ex-
ploits a pre-existent enhancer landscape for regulatory T cell lineage specifi-
cation. Cell 151, 153–166.
Smigiel, K.S., Richards, E., Srivastava, S., Thomas, K.R., Dudda, J.C.,
Klonowski, K.D., and Campbell, D.J. (2014). CCR7 provides localized access
to IL-2 and defines homeostatically distinct regulatory T cell subsets. J. Exp.
Med. 211, 121–136.238 Immunity 42, 227–238, February 17, 2015 ª2015 Elsevier Inc.Spivakov, M., and Fisher, A.G. (2007). Epigenetic signatures of stem-cell iden-
tity. Nat. Rev. Genet. 8, 263–271.
Su, I.-H., Basavaraj, A., Krutchinsky, A.N., Hobert, O., Ullrich, A., Chait, B.T.,
and Tarakhovsky, A. (2003). Ezh2 controls B cell development through histone
H3 methylation and Igh rearrangement. Nat. Immunol. 4, 124–131.
Su, I.-H., Dobenecker, M.-W., Dickinson, E., Oser, M., Basavaraj, A.,
Marqueron, R., Viale, A., Reinberg, D., Wu¨lfing, C., and Tarakhovsky, A.
(2005). Polycomb group protein ezh2 controls actin polymerization and cell
signaling. Cell 121, 425–436.
Tai, X., Cowan, M., Feigenbaum, L., and Singer, A. (2005). CD28 costimulation
of developing thymocytes induces Foxp3 expression and regulatory T cell dif-
ferentiation independently of interleukin 2. Nat. Immunol. 6, 152–162.
Tang, Q., Henriksen, K.J., Boden, E.K., Tooley, A.J., Ye, J., Subudhi, S.K.,
Zheng, X.X., Strom, T.B., and Bluestone, J.A. (2003). Cutting edge: CD28 con-
trols peripheral homeostasis of CD4+CD25+ regulatory T cells. J. Immunol.
171, 3348–3352.
Tumes, D.J., Onodera, A., Suzuki, A., Shinoda, K., Endo, Y., Iwamura, C.,
Hosokawa, H., Koseki, H., Tokoyoda, K., Suzuki, Y., et al. (2013). The poly-
comb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper
type 1 and type 2 cells. Immunity 39, 819–832.
Wei, G., Wei, L., Zhu, J., Zang, C., Hu-Li, J., Yao, Z., Cui, K., Kanno, Y., Roh,
T.-Y., Watford, W.T., et al. (2009). Global mapping of H3K4me3 and
H3K27me3 reveals specificity and plasticity in lineage fate determination of
differentiating CD4+ T cells. Immunity 30, 155–167.
Weiss, J.M., Bilate, A.M., Gobert, M., Ding, Y., Curotto de Lafaille, M.A.,
Parkhurst, C.N., Xiong, H., Dolpady, J., Frey, A.B., Ruocco, M.G., et al.
(2012). Neuropilin 1 is expressed on thymus-derived natural regulatory
T cells, but not mucosa-generated induced Foxp3+ T reg cells. J. Exp. Med.
209, 1723–1742, S1721.
Wilson, C.B., Rowell, E., and Sekimata,M. (2009). Epigenetic control of T-help-
er-cell differentiation. Nat. Rev. Immunol. 9, 91–105.
Xiong, Y., Khanna, S., Grzenda, A.L., Sarmento, O.F., Svingen, P.A., Lomberk,
G.A., Urrutia, R.A., and Faubion, W.A., Jr. (2012). Polycomb antagonizes p300/
CREB-binding protein-associated factor to silence FOXP3 in a Kruppel-like
factor-dependent manner. J. Biol. Chem. 287, 34372–34385.
Xu, K., Wu, Z.J., Groner, A.C., He, H.H., Cai, C., Lis, R.T., Wu, X., Stack, E.C.,
Loda, M., Liu, T., et al. (2012). EZH2 oncogenic activity in castration-resistant
prostate cancer cells is Polycomb-independent. Science 338, 1465–1469.
Yadav, M., Louvet, C., Davini, D., Gardner, J.M., Martinez-Llordella, M.,
Bailey-Bucktrout, S., Anthony, B.A., Sverdrup, F.M., Head, R., Kuster, D.J.,
et al. (2012). Neuropilin-1 distinguishes natural and inducible regulatory
T cells among regulatory T cell subsets in vivo. J. Exp. Med. 209, 1713–
1722, S1711-1719.
Zhang, R., Huynh, A., Whitcher, G., Chang, J., Maltzman, J.S., and Turka, L.A.
(2013). An obligate cell-intrinsic function for CD28 in Tregs. J. Clin. Invest. 123,
580–593.
Zhang, Y., Kinkel, S., Maksimovic, J., Bandala-Sanchez, E., Tanzer, M.C.,
Naselli, G., Zhang, J.G., Zhan, Y., Lew, A.M., Silke, J., et al. (2014). The poly-
comb repressive complex 2 governs life and death of peripheral T cells. Blood
124, 737–749.
Zhou, X., Jeker, L.T., Fife, B.T., Zhu, S., Anderson, M.S., McManus, M.T., and
Bluestone, J.A. (2008). Selective miRNA disruption in T reg cells leads to un-
controlled autoimmunity. J. Exp. Med. 205, 1983–1991.
Zhou, X., Bailey-Bucktrout, S.L., Jeker, L.T., Penaranda, C., Martı´nez-
Llordella, M., Ashby, M., Nakayama, M., Rosenthal, W., and Bluestone, J.A.
(2009). Instability of the transcription factor Foxp3 leads to the generation of
pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000–1007.
